Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening
NCT ID: NCT06971276
Last Updated: 2025-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
101 participants
OBSERVATIONAL
2024-04-03
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens
NCT06327568
Screening Women With Prior HPV for Anal Neoplasia
NCT05217940
Anal Cancer Risk In Women
NCT05835947
Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.
NCT03061435
Epstein-Barr Detection in Oral Cancer
NCT01039272
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Anal cancer
Screening patients diagnosed with anal squamous cell carcinoma (ASCC)
No interventions assigned to this group
AIN3
Screening patients diagnosed with anal intraepithelial neoplasia 3 (AIN3)
No interventions assigned to this group
AIN2
Screening patients diagnosed with anal intraepithelial neoplasia 2 (AIN2)
No interventions assigned to this group
AIN1
Screening patients diagnosed with anal intraepithelial neoplasia 1 (AIN1)
No interventions assigned to this group
HPV Infection
Screening patients diagnosed with HPV infection (no lesion)
No interventions assigned to this group
Controls
Screening patients diagnosed negative for HPV and control patients from the general population.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Control patients from the general population.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts Eye and Ear Infirmary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daniel L. Faden, MD
Assistant Professor, Harvard Medical School
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel L. Faden, M.D.
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Infectious Diseases, Mass General Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18-649
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.